Cargando…

Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer

BACKGROUND: B7-H6 is a novel co-stimulatory ligand that is detected in most malignancies. However, the significance of B7-H6 in small cell lung cancer (SCLC) remains unknown. METHODS: B7-H6 expression was analyzed by immunohistochemistry (IHC) in 103 collected SCLC samples, and its association with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiuqin, Xie, Weiguo, Wang, Zhiqiang, Song, Shu, Qin, Yan, Zhang, Fang, Chen, Fangfang, Cai, Liming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290544/ https://www.ncbi.nlm.nih.gov/pubmed/32566616 http://dx.doi.org/10.21037/atm-20-2548

Ejemplares similares

B7-H4 promotes tumor growth and metastatic progression in lung cancer by impacting cell proliferation and survival
por: Zhang, Xiuqin, et al.
Publicado: (2017)

SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
por: Gray, Elizabeth, et al.
Publicado: (2023)

Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma
por: Mao, Shengqiang, et al.
Publicado: (2023)

PD-1 and its ligands are important immune checkpoints in cancer
por: Dong, Yinan, et al.
Publicado: (2016)

Pediatric medulloblastoma express immune checkpoint B7-H3
por: Li, S., et al.
Publicado: (2022)

Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation
por: Harland, Niklas, et al.
Publicado: (2022)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications
por: Moon, Jihyun, et al.
Publicado: (2021)

Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer
por: Benelli, Roberto, et al.
Publicado: (2023)

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer
por: Wang, Fuli, et al.
Publicado: (2023)

High Mannose Binding Lectin (PFL) from Pseudomonas fluorescens Down-Regulates Cancer-Associated Integrins and Immune Checkpoint Ligand B7-H4
por: Sato, Yuichiro, et al.
Publicado: (2019)

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
por: Zhao, Binghao, et al.
Publicado: (2022)

CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
por: Zhang, Man, et al.
Publicado: (2020)

Immune Checkpoint and Other Receptor-Ligand Pairs Modulating Macrophages in Cancer: Present and Prospects
por: Yang, Yuanyuan, et al.
Publicado: (2022)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
por: Aicher, Wilhelm K., et al.
Publicado: (2021)

Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
por: Shi, An-Ping, et al.
Publicado: (2022)

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
por: Kamali, Ali N., et al.
Publicado: (2023)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer
por: Bazhin, Alexandr V., et al.
Publicado: (2022)

N(6)-methyladenosine (m(6)A) RNA methylation signature as a predictor of stomach adenocarcinoma outcomes and its association with immune checkpoint molecules
por: Mo, Pingfan, et al.
Publicado: (2020)

Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer
por: Cherif, Boutheina, et al.
Publicado: (2021)

Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis
por: Li, Lin‐Lu, et al.
Publicado: (2023)

The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer
por: Zeng, Hao, et al.
Publicado: (2022)

Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients
por: Al-Mterin, Mohammad A., et al.
Publicado: (2022)

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
por: Getu, Ayechew Adera, et al.
Publicado: (2023)

Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA
por: Pan, Jing, et al.
Publicado: (2021)

Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer
por: Yang, Shuo, et al.
Publicado: (2020)

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
por: Park, Jang-June, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
por: Tang, Shengjie, et al.
Publicado: (2022)

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)

Deficiency of N-linked glycosylation impairs immune function of B7-H6
por: Chen, Hanqing, et al.
Publicado: (2023)

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer
por: Han, Shuai, et al.
Publicado: (2023)

Targeting Immune Cell Checkpoints during Sepsis
por: Patil, Naeem K., et al.
Publicado: (2017)

The B7 family of immune-regulatory ligands
por: Collins, Mary, et al.
Publicado: (2005)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Genova, Carlo, et al.
Publicado: (2023)

Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
por: Zhu, Wanshan, et al.
Publicado: (2023)

The N(6)-Methyladenosine-Modified Pseudogene HSPA7 Correlates With the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in Glioblastoma
por: Zhao, Rongrong, et al.
Publicado: (2021)

The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development
por: Picarda, Elodie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_090fabtrb7kfqdap9q81sdcebk